AI ICU ventilation weaning market seen reaching $4.57 billion by 2030

The market for AI-powered ICU ventilation weaning reached $1.61 billion in 2025 and is projected to grow to $4.57 billion by 2030, driven by rising respiratory disease cases, personalized medicine, and wider use of AI in critical care. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - AI-guided ventilator weaning is moving from a niche concept to a larger critical-care market. - The shift could help ICUs reduce ventilation time, lower complications, and improve patient recovery. - The market’s rapid growth signals broader adoption of AI tools in frontline hospital workflows.

What happened: - The Business Research Company published a global market report on the AI-powered ICU ventilation weaning market covering 2026 to 2035. - The market was valued at $1.61 billion in 2025. - The market is projected to rise to $1.99 billion in 2026. - The report forecasts the market will reach $4.57 billion by 2030. - The report cites a 23.3% CAGR for the historical period and 23.1% CAGR for the forecast period.

The details: - AI-assisted ventilation weaning uses live patient data to assess readiness for removing mechanical ventilation. - The technology is designed to optimize ventilator adjustments and reduce complications. - The stated goal is to improve recovery outcomes, shorten ventilation duration, and lower ICU-associated risks. - Growth drivers include higher use of mechanical ventilation, more ICU patients, more complex respiratory management, better critical-care monitoring, and wider adoption of data-guided ICU protocols. - Rising respiratory disease cases are a major demand driver. - The report points to COPD as an example, citing the Australian Institute of Health and Welfare’s June 2024 finding that COPD accounted for 3.6% of Australia’s total disease burden in 2023 and half of the country’s respiratory disease impact. - Personalized medicine is another growth factor. - The report cites the Personalized Medicine Coalition’s February 2024 note that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - Emerging trends include predictive weaning algorithms, real-time ventilator analytics, AI-assisted decision support, automated ventilation management, and efforts to reduce ventilation duration. - The report says expanded 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot graphics, and updated trend analysis. - Download the free sample report. - View the full market report.

Between the lines: - The market’s growth appears tied less to a single product cycle and more to a broader shift toward AI-enabled care optimization in ICUs. - The strongest near-term demand seems likely to come from hospitals seeking more precise ventilator management for older and more respiratory-compromised patients. - The regional split suggests mature health systems are adopting first, while faster growth may come from expanding critical-care infrastructure in Asia-Pacific.

What's next: - The report points to continued uptake of AI-powered critical care solutions and smart ventilator systems. - Hospitals and ICU teams are likely to focus on predictive analytics that can shorten stays and reduce time on ventilation. - Market growth will likely track broader hospital investment in decision-support tools and data-driven clinical workflows. - Contact details for more information were provided by The Business Research Company, including email marketing@tbrc.info and multiple regional phone numbers. - The company also listed its LinkedIn, Facebook, and X accounts for follow-up.